GlassScriptPhysician profile
Cheryl Y Proctor
NPI 1942324645
$1,392.36
in general payments reported to CMS, 2019-2025
20 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $231 · 2022: $16.00 · 2023: $288 · 2024: $514 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,145.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $296.00 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $256.52 | 2021-2025 | |
| Lilly USA, LLC | $140.32 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $115.44 | 2021-2025 | Farxiga, Airsupra |
| Exact Sciences Corporation | $88.56 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $86.26 | 2023-2025 | |
| Amgen INC. | $57.43 | 2023-2025 | Repatha, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.58 | 2021-2023 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $44.48 | 2023-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $41.58 | 2023-2024 | Keveyis |
| Abbott Laboratories | $36.38 | 2023-2025 | Freestyle Libre 3, Eterna |
| Dexcom, INC. | $35.21 | 2025 | Dexcom G6 Transmitter |
| Noctrix Health, INC. | $25.17 | 2025 | Nidra |
| Phathom Pharmaceuticals, INC. | $22.39 | 2024 | Voquezna |
| Hologic Sales and Service, LLC | $20.00 | 2025 | Aptima, Thinprep 2000 Processor |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $17.62 | 2024 | Gemtesa |
| Glaxosmithkline, LLC. | $17.42 | 2024 | Shingrix, Arexvy |
| Abiomed | $15.90 | 2024 | Impella |
| Merck Sharp & Dohme LLC | $15.69 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Sonex Health, INC. | $15.41 | 2025 | Sx-One Microknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Proctor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.